Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organon's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1,407 Mil.
Organon's quarterly Current Accrued Expense
increased
from Dec. 2025 ($1,335 Mil) to Mar. 2026 ($1,424 Mil) but then
declined
from Mar. 2026 ($1,424 Mil) to Jun. 2026 ($1,407 Mil).
Organon's annual Current Accrued Expense
increased
from Dec. 2023 ($1,389 Mil) to Dec. 2024 ($1,411 Mil) but then
declined
from Dec. 2024 ($1,411 Mil) to Dec. 2025 ($1,335 Mil).
The historical data trend for Organon's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of $1,407 Mil mean?
Organon (OGN) has a Current Accrued Expense of $1,407 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Organon and its competitors.
Is Organon's Current Accrued Expense too high?
Organon's current Current Accrued Expense is $1,407 Mil. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Current Accrued Expense compare to AMRN and SCLX?
Organon's Current Accrued Expense of $1,407 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Organon and its competitors. Organon's current Current Accrued Expense is $1,407 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $13.37, compared to a current price of $13.72 — trading 2.6% above its estimated fair value. The current Current Accrued Expense is $1,407 Mil. Organon's overall GF Score™ is 71/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Organon (OGN), the current Current Accrued Expense is $1,407 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be overvalued.
The current stock price of $13.72 is trading 2.6% above its estimated GF Value™ of $13.37.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Current Accrued Expense: $1,407 Mil
GF Value™: $13.37 vs. price of $13.72 (2.6% above fair value)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
